Investigational Drug Information for Aminopterin
✉ Email this page to a colleague
What is the development status for investigational drug Aminopterin?
Aminopterin is an investigational drug.
There have been 138 clinical trials for Aminopterin.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 9th 2009.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Lymphoid, and Precursor Cell Lymphoblastic Leukemia-Lymphoma. The leading clinical trial sponsors are National Cancer Institute (NCI), M.D. Anderson Cancer Center, and Children's Oncology Group.
Summary for Aminopterin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 39 |
| WIPO Patent Applications | 12 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 3 (2009-03-09) |
| Vendors | 40 |
Recent Clinical Trials for Aminopterin
| Title | Sponsor | Phase |
|---|---|---|
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat | Children's Oncology Group | Phase 1/Phase 2 |
| Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | M.D. Anderson Cancer Center | Phase 1/Phase 2 |
Clinical Trial Summary for Aminopterin
Top disease conditions for Aminopterin
Top clinical trial sponsors for Aminopterin
US Patents for Aminopterin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
